Drug Development Pipeline
| Clinical Trial Candidate | Target | Pre-Clinical | Phase I | |
|---|---|---|---|---|
| Deltacel-01 Deltacel™ in combination with low-dose radiation Allogeneic, Non-Viral, Non-engineered off-the-shelf GDT therapy |
 |
Multiple Tumor Cell Markers | ||
| New IND Isocel™ in combination with low-dose radiation Allogeneic, off the-shelf GDT CAR-T therapy |
|
Mesothelin Isoform KRBP Proprietary Target |
H1 2025*Expected Beginning of Activation Process for Clinical Trial |
|
| New IND ALEXIS - ISO-1 Isocel™ Allogeneic, off the-shelf GDT CAR-T therapy |
 |
Mesothelin Isoform KRBP Proprietary Target |
H1 2025*Expected Beginning of Activation Process for Clinical Trial |
|
| New IND Procel™ in combination with low-dose radiation Allogeneic, off the-shelf GDT CAR-T therapy |
|
PD-L1 | H1 2025*Expected Beginning of Activation Process for Clinical Trial |
|
| New IND ALEXIS - PRO-1 Isocel™ Allogeneic, off the-shelf GDT CAR-T therapy |
|
PD-L1 | H1 2025*Expected Beginning of Activation Process for Clinical Trial |
| Clinical Trial Candidate | Target | Progress |
|---|---|---|
| Deltacel-01 Deltacel™ in combination with low-dose radiation Allogeneic, Non-Viral, Non-engineered off-the-shelf GDT therapy |
Multiple Tumor Cell Markers | First Patient Dosed 12/13/2023 |
| New IND Isocel™ in combination with low-dose radiation Allogeneic, off the-shelf GDT CAR-T therapy |
Mesothelin Isoform KRBP Proprietary Target |
H1 2025* Expected Beginning of Activation Process for Clinical Trial |
| New IND ALEXIS - ISO-1 Isocel™ Allogeneic, off the-shelf GDT CAR-T therapy |
Mesothelin Isoform KRBP Proprietary Target |
H1 2025* Expected Beginning of Activation Process for Clinical Trial |
| New IND Procel™ in combination with low-dose radiation Allogeneic, off the-shelf GDT CAR-T therapy |
PD-L1 | H1 2025* Expected Beginning of Activation Process for Clinical Trial |
| New IND ALEXIS - PRO-1 Isocel™ Allogeneic, off the-shelf GDT CAR-T therapy |
PD-L1 | H1 2025* Expected Beginning of Activation Process for Clinical Trial |
*Subject to obtaining sufficient financing to support the progression of the development of those additional clinical trial candidates.
Last Updated: 1/30/2024
R&D Strategy
Expand Tumor Target Recognition
DIAMOND AI™bioinformatics can screen, prioritize, and harmonize novel surface tumor targets:
- Analysis of public and proprietary data bases to expand tumor target data analytics
- Identify alternatively spliced targets, leading to the potential discovery of novel 1st and 2nd-line targets
Lower Manufacturing Costs
One of the many ways Kiromic is working to lower manufacturing costs is through the development of ABBIE (A Binding Based Integration Enzyme), which is a non-viral, genetic engineering platform designed to provide a more precise and less toxic approach to cellular genetic engineering. This exciting platform is progressing rapidly with early preclinical results showing the following promising attribute:
- Safe integration of a linear DNA template which is designed to reduce the risk of insertional mutagenesis and provide for a more uniform expression level of therapeutic proteins, leading to enhanced efficacy and safety.